EAM
ANAB icon

Exome Asset Management’s AnaptysBio ANAB Stock Holding History

Exome Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$333K – 73
2025
Q2 		$333K Sell
15,000
-101,623
-87% -$2.13M 0.25% 57
2025
Q1 		$2.17M Buy
+116,623
New +$1.95M 1.93% 23

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Exome Asset Management's ANAB Position: Q3 2025 in Review

Exome Asset Management sold out of AnaptysBio (ANAB) in Q3 2025, closing a stake of 15,000 shares — an estimated $333K sold.

Exome Asset Management first reported a position in ANAB in Q1 2025 and held it in 2 quarters. The position peaked at $2.17M in Q1 2025. 166 funds tracked by Wall St. Rank hold ANAB as of Q3 2025.

  • Exome Asset Management reported no remaining AnaptysBio position as of Q3 2025 after selling out during the quarter.
  • Exome Asset Management sold 15,000 AnaptysBio shares in Q3 2025, an estimated $333K.
  • Exome Asset Management first reported a position in AnaptysBio in Q1 2025 and held it in 2 quarters.
  • Exome Asset Management's AnaptysBio position peaked at $2.17M in Q1 2025.
  • 166 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.